Citation Report
List of articles citing

Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data

DOI: 10.1007/s40264-013-0115-x
Drug Safety, 2013, 36, 1117-23.

Source: https://exaly.com/paper-pdf/55201413/citation-report.pdf
Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	AE reporting patterns changing, analysis challenges Weber effect. *Reactions Weekly*, **2013**, 1478, 2-2	0	
11	The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. *Drug Safety*, **2014**, 37, 283-94	5.1	72
10	An analysis of the relative frequencies of reported adverse events associated with NSAID administration in dogs and cats in the United Kingdom. *Veterinary Journal*, **2015**, 206, 183-90	2.5	23
9	Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group. *Therapeutic Innovation and Regulatory Science*, **2015**, 49, 65-75	1.2	6
8	Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?. *Clinical Drug Investigation*, **2017**, 37, 415-422	3.2	32
7	Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases. *Clinical Therapeutics*, **2017**, 39, 2006-2023	3.5	5
6	Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. *Therapeutics and Clinical Risk Management*, **2017**, 13, 1195-1203	2.9	17
5	Phase I trials as valid therapeutic options for patients with cancer. *Nature Reviews Clinical Oncology*, **2019**, 16, 773-778	19.4	43
4	Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. *PLoS ONE*, **2019**, 14, e0225572	3.7	8
3	Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study.. *Expert Opinion on Drug Safety*, **2022**,	4.1	0
2	Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data.. *Drug Safety*, **2022**, 1	5.1	0
1	Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.. *Journal of Clinical Virology*, **2022**, 148, 105106	14.5	1